Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Orca Q Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
Orca Q: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AFTX-201 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
AFTX-201: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
TED-A9 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
TED-A9: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ZAG-101 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 October 2026
ZAG-101: Phase 1/2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Dostarlimab-gxly in Endometrial Endometrioid Adenocarcinoma: NCT06278857 Clinical Landscape Report 2026
16 October 2026
NCT06278857 clinical landscape for Endometrial Endometrioid Adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
PBA-0405 in Solid tumor: NCT06273852 Clinical Landscape Report 2026
16 October 2026
NCT06273852 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LTC004 in Locally Advanced Malignant Solid Neoplasm: NCT06277804 Clinical Landscape Report 2026
16 October 2026
NCT06277804 clinical landscape for Locally Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development w…
9 min read
Multiple antigen specific cell therapy(Hengrui Yuanzheng Bio-Technology Co., Ltd.) in Locally Advanced Soft Tissue Sarcoma: NCT06277154 Clinical Landscape Report 2026
16 October 2026
NCT06277154 clinical landscape for Locally Advanced Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
IBI-363 in Advanced Malignant Solid Neoplasm: NCT06281678 Clinical Landscape Report 2026
16 October 2026
NCT06281678 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
XmAb-541 in Endometrial Carcinoma: NCT06276491 Clinical Landscape Report 2026
16 October 2026
NCT06276491 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fibromun in Unresectable Melanoma: NCT06284590 Clinical Landscape Report 2026
16 October 2026
NCT06284590 clinical landscape for Unresectable Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LY007 in B-Cell Lymphoma: NCT06279611 Clinical Landscape Report 2026
16 October 2026
NCT06279611 clinical landscape for B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.